Schering-Plough Corp said itsElocon topical steroid for inflammatory skin disorders has beenapproved for marketing by the U.S. Food and Drug Administrationin cream and ointment forms for once-daily applications.    The company said overseas health agency registrations forElocon are scheduled to be submitted in a number of majormarkets this year and in other areas in 1988. Reuter&#3;